Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.
Genzyme, a sanofi company, has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represent groundbreaking and life-saving advances in medicine.
Sanofi-Genzyme BioVentures (SGBV) is a strategic fund that invests primarily in early-stage innovative companies in the core areas of interest of Sanofi and Genzyme. SGBV’s investments focus on rare diseases, oncology, vaccines, immune-mediated diseases, and breakthrough therapies in other core areas of interest of the Group, as well as integrated care solutions.
The SGBV team also supports other equity-based transactions pursued by other groups within Sanofi and especially co-leads negotiations for Sunrise, another arm within R&D to access early stage innovation. The overall Sunrise objectives are to find new models combining equity, collaboration and licensing to execute novel R&D business structures for tapping into external innovation.
The SGBV team has a hands on approach to managing its investments, and it is important that the new AVP joining the team will share both the company’s values and their relevant life sciences and venture capital expertise. He/she should be able to be actively involved as AVP immediately on their arrival in the business.
If you want to be alerted of new VC job postings, click here.